Foghorn Therapeutics Files 8-K on Security Holder Votes
Ticker: FHTX · Form: 8-K · Filed: Jun 26, 2024 · CIK: 1822462
| Field | Detail |
|---|---|
| Company | Foghorn Therapeutics Inc. (FHTX) |
| Form Type | 8-K |
| Filed Date | Jun 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
Related Tickers: FHTX
TL;DR
Foghorn Therapeutics (FHTX) filed an 8-K for security holder votes - details TBD.
AI Summary
Foghorn Therapeutics Inc. filed an 8-K on June 26, 2024, to report on the submission of matters to a vote of security holders. The filing does not contain details about specific proposals or outcomes of any votes.
Why It Matters
This filing indicates that Foghorn Therapeutics is engaging with its security holders on important corporate matters, which could impact future strategic decisions and shareholder value.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new financial information or significant operational changes.
Key Players & Entities
- Foghorn Therapeutics Inc. (company) — Registrant
- 0001822462 (company) — Central Index Key
- June 26, 2024 (date) — Date of Report
FAQ
What specific matters were submitted to a vote of Foghorn Therapeutics' security holders?
The filing states that matters were submitted to a vote of security holders, but it does not specify what those matters were.
When did the event related to the security holder vote occur?
The earliest event reported in the filing occurred on June 26, 2024.
What is Foghorn Therapeutics' principal executive office address?
Foghorn Therapeutics' principal executive offices are located at 500 Technology Square, Ste 700, Cambridge, MA 02139.
What is Foghorn Therapeutics' IRS Employer Identification Number?
Foghorn Therapeutics' IRS Employer Identification Number is 47-5271393.
Under which section of the Securities Exchange Act of 1934 is this Form 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 655 words · 3 min read · ~2 pages · Grade level 9.4 · Accepted 2024-06-26 16:04:19
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share FHTX The Nasdaq Glo
Filing Documents
- fhtx-20240626.htm (8-K) — 38KB
- 0001628280-24-030137.txt ( ) — 163KB
- fhtx-20240626.xsd (EX-101.SCH) — 2KB
- fhtx-20240626_lab.xml (EX-101.LAB) — 22KB
- fhtx-20240626_pre.xml (EX-101.PRE) — 13KB
- fhtx-20240626_htm.xml (XML) — 3KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 26, 2024 , Foghorn Therapeutics Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The following proposals were submitted to the Company's stockholders at the Annual Meeting: (i) To elect Scott Biller, Ph.D., Thomas J. Lynch, M.D., and Michael Mendelsohn, M.D., as Class I directors, each for a three-year term; and (ii) To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2024. The proposals are described in detail in the Company's Proxy Statement filed with the U.S. Securities and Exchange Commission on May 3, 2024. The number of shares of common stock entitled to vote at the Annual Meeting was 42,585,616 . The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 30,381,145. All matters submitted to a vote of the Company's stockholders at the Annual Meeting were approved and all director nominees were elected. The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below: (i) Election of directors. Director Nominee Votes For Votes Against Abstentions Scott Biller, Ph.D. 20,425,665 4,930,514 10,337 Thomas J. Lynch, M.D. 24,052,377 1,293,218 20,921 Michael Mendelsohn, M.D. 22,357,558 2,988,038 20,920 There were 5,014,629 broker non-votes regarding the election of directors. (ii) Ratification of selection of independent registered public accounting firm. Stockholders ratified the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. The results of the voting included 30,355,319 votes for, 10,376 votes against and 15,450 abstentions. There were no broker non-votes regarding this proposal.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FOGHORN THERAPEUTICS INC. By: /s/ Kristian Humer Kristian Humer Chief Financial Officer Date: June 26, 2024